57598-73-9Relevant academic research and scientific papers
COMPOUNDS AND METHODS OF TREATING DIABETES
-
Page/Page column 139, (2012/09/10)
Hydrogenated pyrido[4,3-b]indoles, pyrido [3, 4-b] indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2B ; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.
PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
-
Page/Page column 159-160, (2011/09/19)
This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder
Neuroleptic Activity in 5-Aryltetrahydro-γ-carbolines
Harbert, Charles A.,Plattner, Jacob J.,Welch, Willard M.,Weissman, Albert,Koe, B. Kenneth
, p. 635 - 643 (2007/10/02)
A series of 5-aryltetrahydro-γ-carbolines was prepared by a novel N-arylation procedure and tested for neuroleptic activity in a rat antiamphetamine model.The systematic exploration of structural parameters leading to 8-fluoro-5-(4-fluorophenyl)-2-4-hydr
